FDA's Projected $20 Mil. In 2013 Biosimilar User Fees Translates Into 68 More Staffers
This article was originally published in The Pink Sheet Daily
Executive Summary
Administration’s proposed fiscal year 2013 spending plan includes $4.5 billion for FDA, with $2 billion or 44% provided by various user fees.
You may also be interested in...
Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
Halfway through the first year of the biosimilar user fee program, fee payments have not lived up to the expectation in President Obama’s FY 2013 budget request. Initial meetings continue to grow but at a slow pace, suggesting sponsors may remain hesitant about the pathway.
FDA Cuts Priority Review Voucher Fee By 32%; J&J In Line For Next Voucher?
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013. That may benefit J&J, assuming a pending tuberculosis agent is approved by FDA.
FDA Cuts Priority Review Voucher Fee By 32%; No Takers For FY 2013
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013.